Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
Kabra M, Barber TJ, Allavena C, Marcelin AG, Di Giambenedetto S, Pasquau J, Gianotti N, Llibre JM, Rial-Crestelo D, De Miguel-Buckley R, Blick G, Turner M, Harrison C, Wynne T, Verdier G, Parry CM, Jones B, Okoli C, Donovan C, Priest J, Letang E. Kabra M, et al. Among authors: pasquau j. Open Forum Infect Dis. 2023 Oct 27;10(11):ofad526. doi: 10.1093/ofid/ofad526. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38033982 Free PMC article.
The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Blanco JR, Arroyo-Manzano D, Rojas-Liévano JF, Crespo M, Bravo I, Pasquau J, Garcia Del Toro M, Herrero C, Rivero A, Moreno S, Llibre JM. Blanco JR, et al. Among authors: pasquau j. AIDS Res Hum Retroviruses. 2015 Sep;31(9):893-7. doi: 10.1089/AID.2015.0016. Epub 2015 Jun 15. AIDS Res Hum Retroviruses. 2015. PMID: 26059859
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Among authors: pasquau j. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
Gutierrez-Valencia A, García C, Viciana P, Milanés-Guisado Y, Fernandez-Magdaleno T, Espinosa N, Pasquau J, López-Cortés LF. Gutierrez-Valencia A, et al. Among authors: pasquau j. PLoS One. 2018 Sep 20;13(9):e0203452. doi: 10.1371/journal.pone.0203452. eCollection 2018. PLoS One. 2018. PMID: 30235244 Free PMC article. Clinical Trial.
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J. Hidalgo-Tenorio C, et al. Among authors: pasquau j. Medicine (Baltimore). 2019 Aug;98(32):e16813. doi: 10.1097/MD.0000000000016813. Medicine (Baltimore). 2019. PMID: 31393412 Free PMC article.
Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Hidalgo-Tenorio C, Vinuesa D, García-Vallecillos C, Muñoz-Medina L, Sequera S, Javier R, López-Ruz MÁ, Sadyrbaeva-Dolgova S, Pasquau J. Hidalgo-Tenorio C, et al. Among authors: pasquau j. Viruses. 2022 Nov 25;14(12):2626. doi: 10.3390/v14122626. Viruses. 2022. PMID: 36560630 Free PMC article.
DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.
Sequera-Arquelladas S, Hidalgo-Tenorio C, López-Cortés L, Gutiérrez A, Santos J, Téllez F, Omar M, Ferra-Murcia S, Fernández E, Javier R, García-Vallecillos C, Pasquau J. Sequera-Arquelladas S, et al. Among authors: pasquau j. Viruses. 2024 Feb 6;16(2):259. doi: 10.3390/v16020259. Viruses. 2024. PMID: 38400035 Free PMC article.
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Jiménez de Ory S, Beltrán-Pavez C, Gutiérrez-López M, Santos MDM, Prieto L, Sainz T, Guillen S, Aguilera-Alonso D, Díez C, Bernardino JI, Mellado MJ, Ramos JT, Holguín Á, Navarro M; Paediatric Cohort of the Spanish National AIDS Network (CoRISpe and CoRISpe-FARO). Jiménez de Ory S, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1886-1892. doi: 10.1093/jac/dkab080. J Antimicrob Chemother. 2021. PMID: 33734374 Free PMC article.
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Hidalgo-Tenorio C, Pasquau J, Vinuesa D, Ferra S, Terrón A, SanJoaquín I, Payeras A, Martínez OJ, López-Ruz MÁ, Omar M, de la Torre-Lima J, López-Lirola A, Palomares J, Blanco JR, Montero M, García-Vallecillos C. Hidalgo-Tenorio C, et al. Among authors: pasquau j. Viruses. 2022 Mar 4;14(3):524. doi: 10.3390/v14030524. Viruses. 2022. PMID: 35336931 Free PMC article. Clinical Trial.
84 results